drugset / Trial / NCT03600870
Midodrine in Hepatopulmonary Syndrome
NaSingle-groupOpen-labelTreatment
Summary
This proof-of-concept clinical trial will determine the safety and tolerability of midodrine in patients with hepatopulmonary syndrome (HPS). Exploratory endpoints will assess the effect of midodrine on oxygenation, intrapulmonary shunting and symptoms.
Timeline
- Start
- 2018-08-02
- Primary completion
- 2020-12-01
- Completion
- 2020-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Midodrine | Small molecule | 10 mg | Oral |